We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Long‐acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice.
- Authors
Schmidt, Heather‐Marie Ann; Rodolph, Michelle; Schaefer, Robin; Baggaley, Rachel; Doherty, Meg
- Abstract
The WHO recommendation on offering CAB-LA as HIV prevention for people at substantial risk for HIV will provide an additional choice for HIV prevention. Long-acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice A decade has passed since the World Health Organization (WHO) first recommended daily oral pre-exposure prophylaxis (PrEP) as an additional HIV prevention option [1]. In addition, optimal HIV testing strategies for CAB-LA need to be established to support CAB-LA integration with existing services.
- Subjects
HIV prevention; PRE-exposure prophylaxis; SEXUALLY transmitted diseases; HIV infections
- Publication
Journal of the International AIDS Society, 2022, Vol 25, Issue 7, p1
- ISSN
1758-2652
- Publication type
Article
- DOI
10.1002/jia2.25963